Comparative Pharmacology
Head-to-head clinical analysis: IGALMI versus KAPVAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IGALMI versus KAPVAY.
IGALMI vs KAPVAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective alpha-2 adrenergic receptor agonist; reduces sympathetic outflow from the central nervous system, resulting in decreased agitation and sedation.
Alpha-2 adrenergic receptor agonist; reduces sympathetic outflow from the CNS, decreasing peripheral vascular resistance and blood pressure.
Sublingual: 120 mcg to 180 mcg as a single dose, administered under the tongue, one time. Maximum single dose: 180 mcg.
0.1 mg orally twice daily, may increase by 0.1 mg/day at weekly intervals; maximum 2.4 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life is 2.5 to 3.5 hours in healthy subjects, with prolonged half-life in patients with hepatic impairment (up to 5-7 hours) or renal impairment (up to 6-8 hours).
Terminal elimination half-life 12-16 hours (range 6-24 h) in adults; prolonged in renal impairment (up to 41 h) and in neonates.
Approximately 75% of the dose is excreted renally as unchanged drug, with the remainder eliminated via biliary/fecal routes (approximately 20%) and minor metabolic clearance.
Renal: 40-60% unchanged; fecal: minimal (<10%); biliary: negligible.
Category C
Category C
Alpha-2 Adrenergic Agonist
Alpha-2 Adrenergic Agonist